TRELEGY ELLIPTA

Fluticasone/Umeclidinium/Vilanterol

ICSLAMALABA DPI

Fluticasone furoate / Umeclidinium / Vilanterol · GlaxoSmithKline

Clinical Reference

Active Medication & Mechanism

Fluticasone furoate ICS
100 mcg or 200 mcg per blister (strip 1)

Synthetic corticosteroid with enhanced glucocorticoid receptor affinity. Provides potent anti-inflammatory activity with once-daily dosing.
Umeclidinium bromide LAMA
62.5 mcg per blister (strip 2)

Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle, preventing cholinergic bronchoconstriction.
Vilanterol trifenatate LABA
25 mcg per blister (strip 2)

Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (≥24 hours) via beta2-receptor stimulation.

// approval varies by strength + age

Asthma

2/3 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
100/62.5/25 mcg	Patients ≥18 years	1 inhalation once daily Maintenance treatment of asthma in adults not adequately controlled with ICS/LABA.	100/62.5/25 mcg	FDA Approved
200/62.5/25 mcg	Patients ≥18 years	1 inhalation once daily For patients requiring higher ICS dose. Not adequately controlled on 100/62.5/25.	200/62.5/25 mcg	FDA Approved
Any strength	Acute bronchospasm	—	—	Not Approved Not a rescue inhaler. Use a SABA for acute symptoms.

COPD

1/2 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
100/62.5/25 mcg	Adults (≥18 years)	1 inhalation once daily Maintenance treatment of patients with COPD. First FDA-approved once-daily single-inhaler triple therapy. Reduces exacerbations and improves lung function.	100/62.5/25 mcg	FDA Approved
200/62.5/25 mcg	Adults (≥18 years)	—	—	Not Approved The 200/62.5/25 strength is NOT indicated for COPD. Only 100/62.5/25 is approved for COPD.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute bronchospasm. Use a SABA.